C4 Therapeutics, Inc.
CCCC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662579
No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 147 institutions reported holding it in 13F filings for Q2 2026, worth $547.6M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding C4 Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 83 | 107 | +24 |
| Shares | 25.1M | 31.9M | +6.85M (+27.3%) |
| Value | $926.8M | $1.21B | +$282.7M (+30.5%) |
New holders (36)
Institutions that held C4 Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (12)
Institutions that held C4 Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Darwin Global Management, Ltd. | 140,034 | $5.18M |
| Federated Hermes, Inc. | 38,975 | $1.44M |
| Bank Julius Baer & Co. Ltd, Zurich | 33,905 | $1.25M |
| Zimmer Partners, LP | 20,000 | $740.0K |
| Affinity Asset Advisors, LLC | 20,000 | $740.0K |
| California Public Employees Retirement System | 19,490 | $721.0K |
| Boothbay Fund Management, LLC | 12,026 | $445.0K |
| Athanor Capital, LP | 10,132 | $375.0K |
| Jane Street Group, LLC | 5,699 | $211.0K |
| Pacer Advisors, Inc. | 1,096 | $41.0K |
| Bank of Montreal | 291 | $10.0K |
| Alpha DNA Investment Management LLC | 84 | $3.00K |